来自 olanzapine 诱导的胰岛素抵抗患者的 miR-486-5p 丰富的细胞外囊泡会对葡萄糖调节功能产生负面影响
Chuyue Tu1, Qian Wu1, Jing Wang1
1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Biochemical pharmacology
|May 24, 2024
概括
接受 olanzapine 治疗的患者的细胞外囊泡 (EV) 可以在老鼠和脂肪细胞中引起胰岛素耐药性. 这些EV中的特定的microRNAs (miRNAs),如miR-486-5p,有助于这些代谢变化.
科学领域:
- 生物化学 生物化学
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥兰扎治疗可能导致葡萄糖代谢障碍,限制其临床使用.
- 细胞外囊泡 (EV) 中的微RNA (miRNA) 是代谢障碍的潜在生物标志物.
研究的目的:
- 调查血EVs在奥兰扎诱导的胰岛素抵抗 (IR) 中个人间差异中的作用.
- 为了识别与奥兰扎诱导的IR相关的EV中的特定miRNAs.
- 探索EV介导的代谢功能障碍的潜在机制.
主要方法:
- 从接受 olanzapine 治疗的 81 名患者中分离出血 EV,并注射给大鼠.
- 高通量测序用于miRNA分析,以比较敏感和非敏感组.
- 试验室内实验涉及同培养脂肪细胞与抗体胺治疗的EVs.
主要成果:
- 个体胰岛素敏感性在患者之间和接受过 olanzapine 治疗的老鼠中各不相同.
- 通过AKT-GLUT4通路,来自 olanzapine诱导的IR患者的EVs在老鼠和脂肪细胞中诱导了代谢异常.
- 在基于IR敏感性的EV中观察到不同的miRNA配置文件,其中miR-486-5p被确定为关键参与者.
结论:
- 血EV在奥兰扎诱导的胰岛素敏感性变化中发挥着重要作用.
- 循环的电动汽车可以传递代谢功能障碍,突出显示它们作为生物标志物和治疗点的潜力.
- miR-486-5p与奥兰扎宾诱导的胰岛素耐药性的发展有关.
相关概念视频
Insulin Secretory Vesicles
4.9K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Glucagon-like Receptor Agonists
318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173
Oral Hypoglycemic Agents: Glinides
153
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
153


